KR910006889B1 - 왁진 조성물 - Google Patents

왁진 조성물 Download PDF

Info

Publication number
KR910006889B1
KR910006889B1 KR1019830000640A KR830000640A KR910006889B1 KR 910006889 B1 KR910006889 B1 KR 910006889B1 KR 1019830000640 A KR1019830000640 A KR 1019830000640A KR 830000640 A KR830000640 A KR 830000640A KR 910006889 B1 KR910006889 B1 KR 910006889B1
Authority
KR
South Korea
Prior art keywords
herpes simplex
simplex virus
wax
asp
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019830000640A
Other languages
English (en)
Korean (ko)
Other versions
KR840003420A (ko
Inventor
에이취 코헨 게리
제이 아이젠버그 로젤린
Original Assignee
유니버어시티 파텐츠 인코포레이팃드
로버트 아이 시겔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26996451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR910006889(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유니버어시티 파텐츠 인코포레이팃드, 로버트 아이 시겔 filed Critical 유니버어시티 파텐츠 인코포레이팃드
Publication of KR840003420A publication Critical patent/KR840003420A/ko
Application granted granted Critical
Publication of KR910006889B1 publication Critical patent/KR910006889B1/ko
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/224—Herpes related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1019830000640A 1982-02-18 1983-02-17 왁진 조성물 Expired KR910006889B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35002182A 1982-02-18 1982-02-18
US06/463,141 US4762708A (en) 1982-02-18 1983-02-04 Materials and methods for herpes simplex virus vaccination
US350021 1983-02-04
US463141 1983-02-04

Publications (2)

Publication Number Publication Date
KR840003420A KR840003420A (ko) 1984-09-08
KR910006889B1 true KR910006889B1 (ko) 1991-09-10

Family

ID=26996451

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830000640A Expired KR910006889B1 (ko) 1982-02-18 1983-02-17 왁진 조성물

Country Status (20)

Country Link
US (1) US4762708A (enExample)
EP (1) EP0101506B1 (enExample)
JP (3) JP2665332B2 (enExample)
KR (1) KR910006889B1 (enExample)
AR (1) AR231496A1 (enExample)
AT (1) ATE54827T1 (enExample)
AU (1) AU554710B2 (enExample)
CA (1) CA1236774A (enExample)
DE (1) DE3381761D1 (enExample)
DK (1) DK172619B1 (enExample)
ES (1) ES8406199A1 (enExample)
FI (2) FI73885C (enExample)
GR (1) GR77900B (enExample)
HU (1) HU195734B (enExample)
IE (1) IE56479B1 (enExample)
IL (5) IL80896A (enExample)
NO (2) NO162366B (enExample)
NZ (1) NZ220771A (enExample)
PH (1) PH25689A (enExample)
WO (1) WO1983002897A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540669A (en) * 1980-09-11 1985-09-10 Merck & Co., Inc. Herpes simplex type I subunit vaccine
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
JPS6051120A (ja) * 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
JPS6153226A (ja) * 1984-08-24 1986-03-17 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニツトワクチンの精製方法
DE3683688D1 (de) * 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
GB8605390D0 (en) * 1986-03-05 1986-04-09 Univ Birmingham Live herpes simplex vaccine
EP0471778A1 (en) * 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
RU2146134C1 (ru) * 1999-06-29 2000-03-10 Ласкавый Владислав Николаевич Антивирусный препарат для инъекций
AU2001286407A1 (en) * 2000-08-01 2002-03-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds derived from the hsv gd protein and methods
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
CA2492598C (en) 2002-07-18 2013-12-17 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
EP1670507A4 (en) * 2003-09-12 2007-10-17 Antigenics Inc VACCINE FOR THE TREATMENT AND PREVENTION OF HERPES SIMPLEX VIRUS INFECTION
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
WO2008030560A2 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
CA2674051C (en) * 2006-12-28 2017-10-31 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US20130028925A1 (en) * 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) * 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
WO2012139106A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus
US9555099B2 (en) 2012-05-16 2017-01-31 Immune Design Corp. Vaccines for HSV-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
IE53176B1 (en) * 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production

Also Published As

Publication number Publication date
DE3381761D1 (de) 1990-08-30
FI833768L (fi) 1983-10-17
FI864102L (fi) 1986-10-10
DK172619B1 (da) 1999-03-01
EP0101506A4 (en) 1984-07-06
PH25689A (en) 1991-09-04
JPS59500216A (ja) 1984-02-16
NO162366B (no) 1989-09-11
FI73885B (fi) 1987-08-31
FI864102A0 (fi) 1986-10-10
FI83880C (fi) 1991-09-10
GR77900B (enExample) 1984-09-25
FI73885C (fi) 1987-12-10
AR231496A1 (es) 1984-12-28
DK479083A (da) 1983-10-17
KR840003420A (ko) 1984-09-08
IL67930A0 (en) 1983-06-15
FI833768A0 (fi) 1983-10-17
IL80895A (en) 1990-02-09
JP2567202B2 (ja) 1996-12-25
EP0101506A1 (en) 1984-02-29
JP2665332B2 (ja) 1997-10-22
FI83880B (fi) 1991-05-31
ATE54827T1 (de) 1990-08-15
WO1983002897A1 (en) 1983-09-01
AU554710B2 (en) 1986-08-28
NO842962L (no) 1983-10-17
US4762708A (en) 1988-08-09
JPH0769924A (ja) 1995-03-14
HU195734B (en) 1988-07-28
JP2669594B2 (ja) 1997-10-29
DK479083D0 (da) 1983-10-17
IL67930A (en) 1990-02-09
ES519875A0 (es) 1984-08-01
IE830332L (en) 1983-08-18
AU1339683A (en) 1983-09-08
NO172745B (no) 1993-05-24
NO833773L (no) 1983-10-17
EP0101506B1 (en) 1990-07-25
IL80896A (en) 1990-02-09
IL80896A0 (en) 1987-03-31
NO172745C (no) 1993-09-01
NZ220771A (en) 1990-09-26
IE56479B1 (en) 1991-08-14
ES8406199A1 (es) 1984-08-01
IL80895A0 (en) 1987-03-31
JPH0797396A (ja) 1995-04-11
CA1236774A (en) 1988-05-17

Similar Documents

Publication Publication Date Title
KR910006889B1 (ko) 왁진 조성물
Eisenberg et al. Localization of epitopes of herpes simplex virus type 1 glycoprotein D
MAcARTHUR et al. Monoclonal antibodies specific for the carboxy terminus of simian virus 40 large T antigen
US4709011A (en) Materials and methods for herpes simplex virus vaccination
Ludwig et al. Biology and neurobiology of Borna disease viruses (BDV), defined by antibodies, neutralizability and their pathogenic potential
Wright et al. Babesia bovis: isolation of a protective antigen by using monoclonal antibodies
JPS61109735A (ja) サイトメガロウイルスに対するワクチン
Ikuta et al. Identification with monoclonal antibodies of glycoproteins of Marek's disease virus and herpesvirus of turkeys related to virus neutralization
Cohen et al. Glycopeptides of the type-common glycoprotein gD of herpes simplex virus types 1 and 2
US6143865A (en) Epstein-Barr virus peptides and antibodies against these peptides
US5149660A (en) Diagnostic reagents relating to herpes simplex virus
JPS62285792A (ja) 帯状疱疹ウイルスに対するワクチン
JP2002506419A (ja) Ａ型肝炎ウイルスポリタンパク質の抗原反応性領域
RU2555530C2 (ru) СПОСОБ ИДЕНТИФИКАЦИИ ПОЛИПЕПТИДОВ И БЕЛКОВ H.parasuis
Sawhney et al. Immunogenicity of axenic Entamoeba histolytica antigen and its fractions
US5549898A (en) Immunogenic anaplasma marginale surface antigens, compositions, and methods of use
Morenkov et al. Immunological characterisation of glycoprotein E of Aujeszky's disease virus
US6177080B1 (en) Polypeptides encoded by Kaposi sarcoma-associated herpes virus the use thereof in diagnosis and therapy
HK1001164B (en) Epstein-barr virus peptides and antibodies against these peptides
MXPA98005626A (es) Composiciones de proteolipido de fijacion de calcio, y metodos

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
G160 Decision to publish patent application
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E601 Decision to refuse application
E902 Notification of reason for refusal
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2002 Appeal before the supreme court

St.27 status event code: A-3-3-V10-V12-crt-PJ2002

J222 Remand (patent court)

Free format text: REMAND (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20010905

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20020911

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20020911